BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Loustaud-Ratti V, Debette-Gratien M, Carrier P. European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift. World J Hepatol 2018; 10(10): 639-644 [PMID: 30386457 DOI: 10.4254/wjh.v10.i10.639]
URL: https://www.wjgnet.com/1948-5182/full/v10/i10/639.htm
Number Citing Articles
1
Laura Bainy Rodrigues de Freitas, Larisse Longo, Deivid Santos, Ivana Grivicich, Mário Reis Álvares-da-Silva. Hepatocellular carcinoma staging systems: Hong Kong liver cancer <i>vs</i> Barcelona clinic liver cancer in a Western populationWorld Journal of Hepatology 2019; 11(9): 678-688 doi: 10.4254/wjh.v11.i9.678
2
Xinhua Zou, Wenzhe Fan, Miao Xue, Jiaping Li. Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) ProgressionCancer Management and Research 2021; : 4013 doi: 10.2147/CMAR.S304591
3
Jean-Michel Pawlotsky, Christian B. Ramers, John F. Dillon, Jordan J. Feld, Jeffrey V. Lazarus. Simplification of Care for Chronic Hepatitis C Virus InfectionSeminars in Liver Disease 2020; 40(04): 392 doi: 10.1055/s-0040-1713657
4
Andrea Bregenzer, Cornelia Krismer, Stefanie Wendel, Patrik Roser, Christoph A. Fux. HCV elimination in a Swiss opioid agonist therapy programme – a cohort studySwiss Medical Weekly 2022; 152(4950): 40009 doi: 10.57187/smw.2022.40009
5
Dmitry V. Garbuzenko. Diagnostic and risk stratification aspects of liver fibrosis progression in chronic hepatitis B and C viral infectionMedical Journal of the Russian Federation 2021; 27(4): 373 doi: 10.17816/0869-2106-2021-27-4-373-384